Allied Market Research

2024

Acute Myeloid Leukemia Therapeutics Market

Acute Myeloid Leukemia Therapeutics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Treatment Type : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Acute myeloid leukemia (AML), is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming cells. In AML, there is a fast production of the abnormal WBCs that get accumulated in the bone marrow, and affect the production of normal blood cells.

The major factors that drive the market growth include advantages of biopharmaceuticals over conventional medicines, rise in geriatric population, unhealthy lifestyle, strong biopharmaceutical pipeline, and development of combination therapies that can treat diseases that were previously untreated. However, high cost of the therapeutic process, and its safety concerns, is expected to hinder the growth of the market. Moreover, ongoing researches have led to discovery of more efficient therapies for cancer treatment, which pose attractive opportunities for the key market players.

The global acute myeloid leukemia therapeutics market is segmented on the basis of treatment type and geography. According to treatment type, the market is divided into cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players profiled in the report include Eli Lilly and Company, Genzyme Corporation, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Celegene Corporation, Cephalon, Inc., and Eisai Inc.

Key Benefits

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis¬†to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market by type elucidates the regional trends.
  • Key players and their strategies are analyzed to understand the competitive outlook of the market.

Acute Myeloid Leukemia Therapeutics Market Report Highlights

Aspects Details
icon_5
By Treatment Type
  • Cytarabine
  • Anthracycline Drugs
    • Daunomycin
    • Idarubicin
    • Mitoxantrone
  • Alkylating Agents
  • Anti Metabolites
  • Tyrosine Kinase Inhibitors
    • Dasatinib (Sprycel)
    • Imatinib (Gleevec)
  • Hormonal Therapy
  • Others
icon_6
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_7
Key Market Players

Eli Lilly and Company, Cephalon, Inc., Ambit Bioscience, Pfizer Inc., Celegene Corporation, Sunesis Pharmaceuticals, Genzyme Corporation, Bristol-Myers Squibb Company, Novartis AG, Eisai Inc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Acute Myeloid Leukemia Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2023-2032